

IPW/K

PTO/SB/21 (08-04)

Approved for use through 07/31/2006. OMB 0681-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/669,869
Filing Date	September 23, 2003
First Named Inventor	Cyrus Rustam Kumana
Art Unit	1616
Examiner Name	Frank I. Choi
Attorney Docket Number	UHK 00091

ENCLOSURES (Check all that apply)

- | | | |
|--|--|--|
| <input checked="" type="checkbox"/> Fee Transmittal Form
<input type="checkbox"/> Fee Attached
<input type="checkbox"/> Amendment/Reply
<input type="checkbox"/> After Final
<input type="checkbox"/> Affidavits/declaration(s)
<input type="checkbox"/> Extension of Time Request
<input type="checkbox"/> Express Abandonment Request
<input checked="" type="checkbox"/> Information Disclosure Statement

<input type="checkbox"/> Certified Copy of Priority Document(s)
<input type="checkbox"/> Reply to Missing Parts/
Incomplete Application
<input type="checkbox"/> Reply to Missing Parts
under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s)
<input type="checkbox"/> Licensing-related Papers

<input type="checkbox"/> Petition
<input type="checkbox"/> Petition to Convert to a
Provisional Application
<input type="checkbox"/> Power of Attorney, Revocation
Change of Correspondence Address
<input type="checkbox"/> Terminal Disclaimer
<input type="checkbox"/> Request for Refund
<input type="checkbox"/> CD, Number of CD(s) _____
<input type="checkbox"/> Landscape Table on CD | <input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Appeal Communication to Board
of Appeals and Interferences
<input type="checkbox"/> Appeal Communication to TC
(Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> Other Enclosure(s) (please identify
below):
Eight (8) Pages PTO-Form 1449;
Seventy-seven (77) References;
and Return Receipt Postcard |
|--|--|--|

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Pabst Patent Group LLP		
Signature			
Printed name	Patrea L. Pabst		
Date	October 31, 2007	Reg. No.	31,284


CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Carla Stone	Date	October 31, 2007

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number

Effective on 12/08/2004.

Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

FEE TRANSMITTAL
For FY 2007☒ Applicant claims small entity status. See 37 CFR 1.27**TOTAL AMOUNT OF PAYMENT** (\$) 180.00**Complete if Known**

Application Number	10/669,869
Filing Date	September 23, 2003
First Named Inventor	Cyrus Rustam Kumana
Examiner Name	1616
Art Unit	Frank I. Choi
Attorney Docket No.	UHK 00091

METHOD OF PAYMENT (check all that apply)☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): _____☒ Deposit Account Deposit Account Number: 50-3129 Deposit Account Name: Pabst Patent Group LLP

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☐ Charge fee(s) indicated below, except for the filing fee
☒ Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17 ☒ Credit any overpayments**WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**FEE CALCULATION****1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

2. EXCESS CLAIM FEES**Fee Description**

Each claim over 20 (including Reissues)

Fee (\$)	Small Entity Fee (\$)
50	25
200	100
360	180

Each independent claim over 3 (including Reissues)

Multiple dependent claims

Total Claims	Extra Claims	Fee (\$)	Fee Paid (\$)
--------------	--------------	----------	---------------

- 20 or HP = _____ x _____ = _____

HP = highest number of total claims paid for, if greater than 20.

Indep. Claims	Extra Claims	Fee (\$)	Fee Paid (\$)
---------------	--------------	----------	---------------

- 3 or HP = _____ x _____ = _____

HP = highest number of independent claims paid for, if greater than 3.

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof	Fee (\$)	Fee Paid (\$)
--------------	--------------	--	----------	---------------

- 100 = _____ / 50 = _____ (round up to a whole number) x _____ = _____

4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)

Other (e.g., late filing surcharge): Information Disclosure Statement

Fees Paid (\$)

\$180.00

SUBMITTED BY

Signature	Registration No. (Attorney/Agent) 31,284	Telephone 404-879-2151
Name (Print/Type) Patrea L. Pabs		Date October 31, 2007

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Cyrus Rustam Kumana and Yok-Lam Kwong

Serial No.: 10/669,869

Art Unit: 1616

Filed: September 23, 2003

Examiner: Frank I. Choi

For: *FORMULATION OF ORAL COMPOSITIONS COMPRISING ARSENIC
TRIOXIDE AND METHODS OF USE*

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit a Supplemental Information Disclosure Statement, including eight (8) pages of Form PTO-1449 and copies of seventy seven (77) documents cited therein. Copies of the six (6) documents in bold marked with an asterisk in the list below will be submitted subsequent to the filing of this Supplemental Information Disclosure Statement, under separate cover.

This Supplemental Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(c) prior to a final Office Action on the merits. The Commissioner is authorized to charge \$180.00, the fee set forth under 37 CFR § 1.17(p), to Account No. 50-3129. It is believed that no additional fee is required with this submission. However, should an additional fee be required, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 50-1329

11/05/2007 ATRINH 00000024 503129 10669869
01 FC:1806 180.00 DA

Publications

ABROUN, et al., "Receptor synergy of interleukin-6 (IL-6) and insulin-like growth factor-I in myeloma cells that highly express IL-6 receptor alpha [corrected]", *Blood*, 103(6):2291-8 (2004).

AKAY and GAZITT, "Arsenic trioxide selectively induces early and extensive apoptosis via the APO2/caspase-8 pathway engaging the mitochondrial pathway in myeloma cells with mutant p53", *Cell Cycle*, 2(4):358-68 (2003).

ALT, et al., "Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation" *Genes Dev*, 14:3102-14 (2000).

AU, et al., "Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide", *Br J Haematol.*, 117(1):130-2 (2002).

BAHLIS, et al., "Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma", *Clin Cancer Res.*, 8(12):3658-68 (2002).

***BERENSON, et al., "A prospective, open-label safety and efficacy study of combination treatment with melphalan, arsenic trioxide, and ascorbic acid in patients with relapsed or refractory multiple myeloma", *Clin Lymphoma*, 5(2):130-4 (2004).**

BURKE, et al., "BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice", *J Biol Chem*, 278:1450-6 (2003).

CAMACHO, et al., "Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide", *J. CLin. Oncol.*, 18:2620-5 (2000).

CARPENTER, "Employment of the epidermal growth factor receptor in growth factor-independent signaling pathways", *J Cell Biol.*, 146(4):697-702 (1999).

CATLEY, et al., "Perspectives for combination therapy to overcome drug-resistant multiple myeloma", *Drug Resist Updat.*, 8(4):205-18 (2005).

CHEN, et al., "Use of arsenic trioxide (As₂O₃) in the treatment of acute promyelocytic leukemia (APL): I. As₂O₃ exerts dose-dependent dual effects on APL cells" *Blood*, 89(9):3345-53 (1997).

CHOONG and COHEN, "Epidermal growth factor receptor directed therapy in head and neck cancer", *Crit Rev Oncol Hematol.*, 57(1):25-43 (2006).

COHEN, et al., "The expanding role of systemic therapy in head and neck cancer", *J Clin Oncol.*, 22(9):1743-52 (2004)

COLE, et al., "Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event", *Biochem J.*, 377:249-55 (2004).

CROSS, et al., "Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B", *Nature*, 378:785-9 (1995).

DAVISON, et al., "JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells", *Blood*, 103(9):3496-502 (2004).

DEL RAZO, et al., "Stress proteins induced by arsenic", *Toxicol Appl Pharmacol.*, 177(2):132-48 (2001).

DIEHL, et al., "Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization", *Genes Dev*, 12:3499-511 (1998).

DIEHL, et al., "Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway", *Genes Dev*, 11:957-72 (1997).

FAN, et al., "Phospholipase C-independent activation of glycogen synthase kinase-3beta and C-terminal Src kinase by Galphaq", *J Biol Chem*, 278:52432-6 (2003).

FERLIN, et al., "Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway", *Br J Haematol.*, 111(2):626-34 (2000).

FORSTPOINTER, et al. "The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group" *Blood*, 104:3064-71 (2004).

GARTENHAUS, et al., "Arsenic trioxide cytotoxicity in steroid and chemotherapy-resistant myeloma cell lines: enhancement of apoptosis by manipulation of cellular redox state", *Clin Cancer Res.*, 8(2):566-72 (2002).

GOY, et al., "Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma" *J Clin Oncol*, 23:667-75 (2005).

GRANDIS, et al., "Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival", *J Natl Cancer Inst.*, 90:824-32 (1998).

GUO, et al., "Phosphorylation of cyclin D1 at Thr 286 during S phase leads to its proteasomal degradation and allows efficient DNA synthesis" *Oncogene*, 24:2599-612 (2005).

GUO, et al., "Post-transcriptional regulation of cyclin D1 expression during G2 phase" *Oncogene*, 21:7545-56 (2002).

HARTIGAN, et al., "Glycogen synthase kinase 3beta is tyrosine phosphorylated by PYK2", *Biochem Biophys Res Commun.*, 284:485-9 (2001).

HARTIGAN, et al., "Transient increases in intracellular calcium result in prolonged site-selective increases in Tau phosphorylation through a glycogen synthase kinase 3beta-dependent pathway", *J Biol Chem*, 274:21395-401 (1999).

HICKE, "Protein regulation by monoubiquitin", *Nat Rev Mol Cell Biol*, 2:195-201 (2001).

HUANG, et al., "Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia", *Br J Haematol.*, 103(4):1092-5 (1998).

HUBBARD and TILL, "Protein tyrosine kinase structure and function", *Annu Rev Biochem.*, 69:373-98 (2000).

HUGHES, et al., "Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation", *EMBO J*, 12:803-8 (1993).

HUSSEIN, et al., "Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma", *Br J Haematol.*, 125(4):470-6 (2004).

***JANNE, "Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populations", *Semin Oncol.*, 32(6 Suppl 10):S9-15 (2005).**

JEMAL, et al., "Cancer statistics, 2005", *CA Cancer J Clin.*, 55(1):10-30 (2005).

KAUFFMANN-ZEH, et al., "Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB", *Nature*, 385:544-8 (1997).

KAUFMANN et al., "Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma", *Blood*, 104:2269-71 (2004).

KIM, et al., "The novel tyrosine kinase ZAK1 activates GSK3 to direct cell fate specification", *Cell*, 99:399-408 (1999).

KWAK, et al., "IkappaB kinase alpha regulates subcellular distribution and turnover of cyclin D1 by phosphorylation", *J Biol Chem*, 280:33945-52 (2005).

KWONG, et al., "Delicious poison: arsenic trioxide for the treatment of leukemia", *Blood*, 89(9):3487-8 (1997).

KWONG, et al., "Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study", *Am J Hematol.*, 66:274-9 (2001).

KWONG, "Arsenic trioxide in the treatment of haematological malignancies", *Expert Opin Drug Saf.*, 3(6):589-97 (2004).

LALEMAND-BREITENBACH, et al., "Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As₂O₃-induced PML or PML/retinoic acid receptor alpha degradation", *J Exp Med.*, 193(12):1361-71 (2001).

LENZ, et al., "Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)", *J Clin Oncol.*, 23:1984-92 (2005).

LESORT, et al., "Insulin transiently increases tau phosphorylation: involvement of glycogen synthase kinase-3beta and Fyn tyrosine kinase", *J Neurochem*, 72:576-84 (1999).

LING, et al., "NF-kappaB-inducing kinase activates IKK-alpha by phosphorylation of Ser-176", *Proc Natl Acad Sci U S A.*, 95:3792-7 (1998).

LIU, et al., "Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL.", *Blood*, 101(10):4078-87 (2003).

LU, et al., "Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report", *Blood*, 99(9):3136-43 (2002).

MALININ, et al., "MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1", *Nature*, 385:540-4 (1997).

MARMOR and YARDEN, "Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases", *Oncogene*, 23(11):2057-70 (2004).

MOSESSON, et al., "Endocytosis of receptor tyrosine kinases is driven by monoubiquitylation, not polyubiquitylation", *J Biol Chem.*, 278(24):21323-6 (2003).

MUNSHI, "Arsenic trioxide: an emerging therapy for multiple myeloma", *Oncologist*, 6 Suppl 2:17-21 (2001).

***NI, et al., "Pharmacokinetics of intravenous arsenic trioxide in the treatment of acute promyelocytic leukemia", *Chin Med J (Engl.)*, 111(12):1107-10 (1998).**

NIU, et al., "Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients", *Blood*, 94(10):3315-24 (1999).

O'CONNOR, et al., "Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma", *J Clin Oncol*, 23:676-84 (2005).

OHNISHI, et al., "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia", *Ann Intern Med.*, 133(11):881-5 (2000).

PARK, et al., "Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis", *Cancer Res.*, 60(11):3065-71 (2000).

***POMERANTZ and GRANDIS, "The epidermal growth factor receptor signaling network in head and neck carcinogenesis and implications for targeted therapy", *Semin Oncol.*, 31(6):734-43 (2004).**

QIAN, et al., "New perspectives in arsenic-induced cell signal transduction", *J Inorg Biochem.*, 96(2-3):271-8 (2003).

QIANG, et al., "Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk", *Blood*, 99(11):4138-46 (2002).

ROMAQUERA, et al., "High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine" *J Clin Oncol*, 23:7013-23 (2005).

ROODMAN, "Pathogenesis of myeloma bone disease", *Blood Cells Mol Dis.*, 32(2):290-2 (2004).

SAYAS, et al., "GSK-3 is activated by the tyrosine kinase Pyk2 during LPA1-mediated neurite retraction", *Mol Biol Cell*, 17:1834-44 (2006).

SHEN, et al., "Use of arsenic trioxide (As₂O₃) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients", *Blood*, 89(9):3354-60 (1997).

SHERR, "Cancer cell cycles" *Science*, 274:1672-7 (1996).

SHERR, et al., "The RB and p53 pathways in cancer" *Cancer Cell*, 2:103-112 (2002).

SIMEONOVA, et al., "c-Src-dependent activation of the epidermal growth factor receptor and mitogen-activated protein kinase pathway by arsenic. Role in carcinogenesis", *J Biol Chem.*, 277(4):2945-50 (2002).

SOIGNET, et al., "Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide", *N Engl J Med.*, 339(19):1341-8 (1998).

SOIGNET, et al., "United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia", *J Clin Oncol.*, 19(18):3852-60 (2001).

STERNSDORF, et al., "PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia", *Mol Cell Biol.*, 19(7):5170-8 (1999).

SWERDLOW, et al., Mantle Cell Lymphoma, in Jaffe, E.S. et al. (ed.), WHO Classification of Tumors, (2001) 168-170.

TAI, et al., "Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling", *Cancer Res.*, 63(18):5850-8 (2003).

TALLMAN, et al., "Acute promyelocytic leukemia: evolving therapeutic strategies", *Blood*, 99(3):759-67 (2002).

The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma", *Blood*, 89:3909-3918 (1997).

TSUJIMOTO, et al., "Clustering of breakpoints on chromosome 11 in human B-cell neoplasms with the t(11;14) chromosome translocation", *Nature*, 315:340-3 (1985).

TSUJIMOTO, et al., "Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation" *Science*, 224:1403-6 (1994).

VAN DE DONK, et al., "Growth factors and antiapoptotic signaling pathways in multiple myeloma", *Leukemia*, 19(12):2177-85 (2005).

VANHAESEBROECK, et al., "Phosphoinositide 3-kinases: a conserved family of signal transducers", *Trends Biochem Sci*, 22:267-72 (1997).

WITZIG "Current treatment approaches for mantle-cell lymphoma", *J Clin Oncol*, 23:6409-14 (2005).

WITZIG, et al., "Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma", *J Clin Oncol*, 23:5347-56 (2005).

***YAMAUCHI, et al., "Metabolism and excretion of orally administrated arsenic trioxide in the hamster", *Toxicology*, 34(2):113-21 (1985).**


***YANG and FRENKEL, "Arsenic-mediated cellular signal transduction, transcription factor activation, and aberrant gene expression: implications in carcinogenesis", *Environ Pathol Toxicol Oncol*, 21(4):331-42 (2002).**

U.S.S.N.: 10/669,869
Filed: September 23, 2003
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,



Patrea L. Pabst
Reg. No. 31,284

Dated: October 31, 2007

PABST PATENT GROUP LLP
400 Colony Square, Suite 1200
1201 Peachtree Street
Atlanta, Georgia 30361
(404) 879-2151 (Telephone)
(404) 879-2160 (Fax)